Need Assistance?

US & Canada:
+
UK: +

FAQs

Resources

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

Application Area

Galacto-RGD

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Galacto-RGD is a radio-labeled analogue that can be used to study the expression of α5β3 integrin in tumor cells.

Category

Others

Catalog number

BAT-015368

CAS number

922175-70-0

Molecular Formula

C34H52N10O12

Molecular Weight

792.85

Specification
Reference Reading

IUPAC Name

2-[(2S,5R,8S,11S)-8-[4-[[(2S,3R,4R,5R,6S)-6-(aminomethyl)-3,4,5-trihydroxyoxane-2-carbonyl]amino]butyl]-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid

Synonyms

Cyclo(RGDfK(SAA)); [(2S,5R,8S,11S)-8-[4-({[(2S,3R,4R,5R,6S)-6-(Aminomethyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl]carbonyl}amino)butyl]-5-benzyl-11-(3-carbamimidamidopropyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl]acetic acid

Appearance

White Lyophilized Powder

Purity

95%

Density

1.61±0.1 g/cm3

Sequence

Cyclo(-Arg-Gly-Asp-D-Phe-Lys(SAA))

Storage

Store at -20°C

Solubility

Soluble in Water

InChI

InChI=1S/C34H52N10O12/c35-15-22-25(48)26(49)27(50)28(56-22)33(55)38-11-5-4-9-19-30(52)42-18(10-6-12-39-34(36)37)29(51)40-16-23(45)41-21(14-24(46)47)32(54)44-20(31(53)43-19)13-17-7-2-1-3-8-17/h1-3,7-8,18-22,25-28,48-50H,4-6,9-16,35H2,(H,38,55)(H,40,51)(H,41,45)(H,42,52)(H,43,53)(H,44,54)(H,46,47)(H4,36,37,39)/t18-,19-,20+,21-,22-,25-,26+,27+,28-/m0/s1

InChI Key

GUPUFVWCDYSPBQ-WTONCQCASA-N

Canonical SMILES

C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCCCNC(=O)C2C(C(C(C(O2)CN)O)O)O)CC3=CC=CC=C3)CC(=O)O

1.Diet intervention reduces uptake of αvβ3 integrin-targeted PET tracer 18F-galacto-RGD in mouse atherosclerotic plaques.

Saraste A1, Laitinen I, Weidl E, Wildgruber M, Weber AW, Nekolla SG, Hölzlwimmer G, Esposito I, Walch A, Leppänen P, Lisinen I, Luppa PB, Ylä-Herttuala S, Wester HJ, Knuuti J, Schwaiger M. J Nucl Cardiol. 2012 Aug;19(4):775-84. doi: 10.1007/s12350-012-9554-5. Epub 2012 Apr 20.

BACKGROUND: Expression of α(v)β(3) integrin has been proposed as a marker for atherosclerotic lesion inflammation. We studied whether diet intervention reduces uptake of α(v)β(3) integrin-targeted positron emission tomography tracer (18)F-galacto-RGD in mouse atherosclerotic plaques.

2.68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process.

Pohle K1, Notni J, Bussemer J, Kessler H, Schwaiger M, Beer AJ. Nucl Med Biol. 2012 Aug;39(6):777-84. doi: 10.1016/j.nucmedbio.2012.02.006. Epub 2012 Mar 22.

INTRODUCTION: (18)F-Galacto-cyclo(RGDfK) is a well investigated tracer for imaging of ανβ3 expression in vivo, but suffers from the drawback of a time consuming multistep synthesis that can hardly be established under GMP conditions. In this study, we present a direct comparison of the pharmacokinetic properties of this tracer with (68)Ga-NODAGA-cyclo(RGDyK), in order to assess its potential as an alternative for (18)F-Galacto-cyclo(RGDfK).